FDA Grants Accelerated Approval to Sonrotoclax for Relapsed Mantle Cell Lymphoma

The decision

On May 13, 2026, the FDA granted accelerated approval to sonrotoclax, sold as Beqalzi.

It is cleared for adults with mantle cell lymphoma that has relapsed or is refractory, after at least two lines of systemic therapy. One of those lines must have included a BTK inhibitor.

"Relapsed" means the lymphoma came back. "Refractory" means it never responded in the first place. Accelerated approval means the FDA cleared the drug on an early measure of benefit while confirmatory work continues.

What mantle cell lymphoma is

NCI describes mantle cell lymphoma as a B-cell type of non-Hodgkin lymphoma that usually appears in middle-aged or older adults.

It starts in the lymph nodes and spreads to the spleen, bone marrow, and blood. It sometimes reaches the esophagus, stomach, and intestines.

The cells carry a distinctive marker. NCI notes that people with mantle cell lymphoma have too much of a protein called cyclin-D1, or a particular gene change in the lymphoma cells. That is how a pathologist tells it apart from other B-cell lymphomas.

NCI also records something that surprises people. In some patients with no signs or symptoms, delaying the start of treatment does not affect the outlook. Our page on mantle cell lymphoma covers that in more detail.

How the drug works

Sonrotoclax is a BCL-2 inhibitor.

BCL-2 is a protein that blocks apoptosis, the built-in process by which a damaged cell destroys itself. Many lymphoma cells survive by making too much of it. Blocking BCL-2 removes that shield and lets the cell die.

The drug is taken by mouth. It sits in the family covered by our overview of targeted therapy, because it aims at one protein rather than at dividing cells in general.

The evidence

The FDA cited BGB-11417-201, registered as NCT05471843. It was a single-arm, multicenter trial in 103 adults with relapsed or refractory mantle cell lymphoma. All had already received anti-CD20-based therapy and a BTK inhibitor.

Single-arm means there was no comparison group. Everyone got sonrotoclax, and the measures were how many people responded and how long responses lasted, judged by an independent review committee using the Lugano criteria.

The overall response rate was 52%, with a 95% confidence interval of 42% to 62%. The median time to a response was 1.9 months.

The median duration of response was 15.8 months. Its confidence interval runs from 7.4 months to "not estimable," meaning the upper end could not be calculated yet. Median follow-up was about 11.9 months.

What taking it involves

Dosing does not start at the full dose. The regimen opens with a four-week ramp-up phase, then settles at 320 mg by mouth once a day, continuing until the disease progresses or the side effects become unacceptable.

The ramp-up exists for one reason: tumor lysis syndrome. When many cancer cells die at once, their contents flood the bloodstream and can overwhelm the kidneys and disturb heart rhythm. Building the dose slowly spreads that out.

The prescribing information carries warnings for tumor lysis syndrome, serious infections, and neutropenia, meaning a low count of the white cells that fight bacteria.

Of 115 people with mantle cell lymphoma assessed for safety, 37% had a serious adverse reaction. Pneumonia was the most common, at 10%.

The review ran under Project Orbis, an FDA program for reviewing cancer drugs alongside international regulators, with the European Medicines Agency as an observer. The application also received priority review, breakthrough designation, and orphan drug designation.

When to get checked

For lymphoma itself, NCI says to check with a doctor about:

• Swelling in the lymph nodes of the neck, underarm, or groin.
• Fever with no known cause.
• Drenching night sweats.
• Weight loss with no known cause.
• Feeling very tired.

Fever, drenching night sweats, and weight loss occurring together have a name in lymphoma care: B symptoms. They factor into staging and treatment choice, so it helps to describe them plainly rather than downplay them.

For anyone taking sonrotoclax, two situations need a same-day call. A fever, because neutropenia turns ordinary infections dangerous. And, during the ramp-up weeks, symptoms of tumor lysis syndrome such as reduced urination, muscle cramps, an irregular heartbeat, nausea, or confusion.

The wider picture

The American Cancer Society projects about 79,320 new non-Hodgkin lymphoma diagnoses and 19,970 deaths in the United States in 2026, and SEER, the federal cancer surveillance program, posts that projection. SEER's own follow-up gives five-year relative survival across all types of 74.3% for people diagnosed from 2016 through 2022.

Non-Hodgkin lymphoma is not one disease, and mantle cell lymphoma is a small share of it. That registry figure covers dozens of subtypes with very different courses, and it does not describe anyone in particular.

What this approval cannot tell you

A 52% response rate in a single-arm trial does not show that people live longer. There was no control group, so there is nothing to compare against.

Accelerated approval is conditional. It rests on response rate and duration of response, and it can be converted to full approval or withdrawn once confirmatory data arrive.

The indication is also narrow by design. It applies after at least two prior lines including a BTK inhibitor, and it says nothing about earlier settings.

Whether it fits one person depends on prior treatments, kidney function, infection risk, and the judgment of an oncology team working from the full prescribing information.

Sources

• FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma
• ClinicalTrials.gov record for NCT05471843 (BGB-11417-201)
• NCI PDQ: Adult Non-Hodgkin Lymphoma Treatment (Patient Version)
• NCI SEER Cancer Stat Facts: Non-Hodgkin Lymphoma

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.